Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Combiflex is a brand name used for two distinct pharmaceutical products. One version is a combination analgesic containing paracetamol (acetaminophen), salicylamide, and caffeine, which is used for the symptomatic relief of mild to moderate pain and fever. The second, and more clinically prominent in the context of parenteral therapy, is a line of multi-chamber bags (e.g., Combiflex Lipid Central and Combiflex Lipid Peri) manufactured by Otsuka Pharmaceutical. These products provide total parenteral nutrition (TPN) and consist of a balanced mixture of amino acids, electrolytes, glucose, and a lipid emulsion (typically soybean oil). They are designed for intravenous administration to patients who cannot receive adequate nutrition through oral or enteral routes, such as those with severe gastrointestinal disorders, malabsorption, or those recovering from major surgery.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Combiflex.